EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pipeline to evaluate YAP-TEAD inhibitors indicates TEAD inhibition represses NF2 -mutant mesothelioma

Richard Cunningham iD, Siyang Jia, Krishna Purohit, Michaela Noskova Fairley, Marcin K Maniak, Yue Lin, Ning Sze Hui, Rebecca E Graham iD, Adriano G Rossi, Justyna Cholewa-Waclaw, Pierre O Bagnaninchi iD, Neil O Carragher iD und 1 weitere

Life Science Alliance · 2025-10 · 8 (10) · e202503241

DOI: 10.26508/lsa.202503241 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life Science Alliance, online erschienen am 31.07.2025. Verfasst von Richard Cunningham und 12 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Inflammation Research, Institute for Regeneration and Repair, The University of Edinburgh, BioQuarter, Edinburgh, UK. Hauptthemen laut MEDLINE: Mesothelioma, Transcription Factors, Neurofibromin 2, Adaptor Proteins, Signal Transducing. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Worldwide Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As the core, tumorigenic downstream effectors of the Hippo signalling pathway, YAP/TAZ and the TEAD family of transcription factors represent attractive targets for drug discovery efforts within cancer research. This is particularly true in the context of pleural mesothelioma, in which there are many recent preclinical developments and clinical trials evaluating the efficacy of TEAD inhibitors. The range of inhibitors has shown great promise, but comparisons of their performances are so far limited. Here, we develop a high-content pipeline that enables a comparative analysis of currently developed YAP/TAZ-TEAD inhibitors. We take advantage of isogenic cellular models that enable us to examine inhibitor specificity. We identify genetic compensation of the Hippo pathway transcriptional module, with implications for therapeutic targeting, and implement Cell Painting to develop a detailed morphological profiling pipeline that enables further characterisation, quantification, and analysis of off-target effects. Our pipeline is scalable and allows us to establish specificity and comparative potency within cancer-relevant assays in a clinically relevant cellular model of pleural mesothelioma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MesotheliomaTranscription FactorsNeurofibromin 2Adaptor Proteins, Signal TransducingDNA-Binding ProteinsHumansYAP-Signaling ProteinsCell Line, TumorTEA Domain Transcription FactorsSignal TransductionMutationMesothelioma, MalignantHippo Signaling PathwayPleural NeoplasmsLung NeoplasmsGene Expression Regulation, Neoplastic

Substanzen

Transcription FactorsYAP-Signaling ProteinsNeurofibromin 2YAP1 protein, humanTEA Domain Transcription FactorsAdaptor Proteins, Signal TransducingDNA-Binding Proteins

Autor:innen und Institutionen

  • Centre for Inflammation Research, Institute for Regeneration and Repair, The University of Edinburgh, BioQuarter, Edinburgh, UK.
  • Centre for Clinical Brain Sciences, Anne Rowling Regenerative Neurology Clinic, The University of Edinburgh, Edinburgh, UK.
  • High Content Screening Facility, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, UK.
  • Centre for Regenerative Medicine, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, UK.
  • Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK.
  • Centre for Inflammation Research, Institute for Regeneration and Repair, The University of Edinburgh, BioQuarter, Edinburgh, UK Carsten.G.Hansen@ed.ac.uk.

ORCID-Profile: Richard Cunningham, Rebecca E Graham, Pierre O Bagnaninchi, Neil O Carragher, Carsten Gram Hansen

Förderung

  • Worldwide Cancer Research

Zitieren

APA

Cunningham, R., Jia, S., Purohit, K., Fairley, M. N., Maniak, M. K., Lin, Y., Hui, N. S., Graham, R. E., Rossi, A. G., Cholewa-Waclaw, J., Bagnaninchi, P. O., Carragher, N. O., & Hansen, C. G. (2025). Pipeline to evaluate YAP-TEAD inhibitors indicates TEAD inhibition represses NF2 -mutant mesothelioma. Life Science Alliance, 8(10), e202503241. https://doi.org/10.26508/lsa.202503241

Vancouver

Cunningham R, Jia S, Purohit K, Fairley MN, Maniak MK, Lin Y, et al. Pipeline to evaluate YAP-TEAD inhibitors indicates TEAD inhibition represses NF2 -mutant mesothelioma. Life Science Alliance. 2025;8(10):e202503241. doi:10.26508/lsa.202503241

BibTeX
@article{Cunningham2025,
  author = {Cunningham, Richard and Jia, Siyang and Purohit, Krishna and Fairley, Michaela Noskova and Maniak, Marcin K and Lin, Yue and Hui, Ning Sze and Graham, Rebecca E and Rossi, Adriano G and Cholewa-Waclaw, Justyna and Bagnaninchi, Pierre O and Carragher, Neil O and Hansen, Carsten Gram},
  title = {Pipeline to evaluate YAP-TEAD inhibitors indicates TEAD inhibition represses NF2 -mutant mesothelioma},
  journal = {Life Science Alliance},
  year = {2025},
  volume = {8},
  number = {10},
  pages = {e202503241},
  doi = {10.26508/lsa.202503241}
}
Kostenlos starten →